Amplia Therapeutics recruitment milestone for ACCENT trial

Amplia Therapeutics Limited (ASX: $ATX) has achieved a significant milestone by successfully recruiting 26 patients for the Phase 2a stage of the ACCENT trial. The trial aims to investigate the activity of narmafotinib, in combination with standard-of-care chemotherapy, in advanced pancreatic cancer patients.

Executive commentary on ACCENT trial recruitment milestone

Amplia CEO and MD Dr Chris Burns stated, 'The recruitment of our 26th patient is an important milestone for the Company. With 26 patients enrolled, and based on experience to date, we believe that the outcome from the interim analysis will be reported around the beginning of Q4 2024. Imaging data for the first patients from this cohort is now being collated and efficacy signals to date mirror the positive data previously reported from the Phase 1b stage of the trial.'

Summary of Amplia Therapeutics ACCENT trial milestone

Amplia Therapeutics has successfully completed the recruitment of 26 patients for the Phase 2a stage of the ACCENT trial, marking a significant advancement in the investigation of narmafotinib for the treatment of advanced pancreatic cancer. The company anticipates reporting the outcome from the interim analysis around the beginning of Q4 2024. The ACCENT trial aims to assess the efficacy of narmafotinib in combination with standard-of-care chemotherapy, and the positive signals observed thus far are encouraging. Amplia Therapeutics continues to make progress in its mission to develop Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis, with a particular focus on fibrotic cancers such as pancreatic and ovarian cancer.